Novavax Files for Interim Authorization of COVID-19 Vaccine in Singapore

GAITHERSBURG, Md., Nov. 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its submission to the Singapore Health Sciences Authority (HSA) for interim authorization of its COVID-19 vaccine under the Pandemic Special Access Route (PSAR). "Today's filing reinforces our ongoing commitment to delivering...

Related Keywords

Mexico ,India ,Australia ,Philippines ,New Zealand ,United Kingdom ,Singapore ,Indonesia ,Canada ,South Korea ,Laura Keenan ,Erika Schultz ,Stanleyc Erck ,Alexandra Roy ,Alison Chartan ,Instagram ,Linkedin ,Twitter ,World Health Organization ,Nasdaq ,Singapore Health Sciences Authority ,Exchange Commission ,Serum Institute Of India Pvt ,European Union ,Facebook ,Novavax Inc ,Pandemic Special Access Route ,Chief Executive Officer ,Serum Institute ,Emergency Use Authorization ,Emergency Use Listing ,Biologics License Application ,Financial Condition ,Novavax Annual Report ,Quarterly Reports ,